Evidence in favour
- 4 distinct acquisition events survive duplicate and security-type controls.
- Participation spans 3 named insiders rather than one filing source.
Company insider dossier
Summit Therapeutics PLC insider intelligence
SMMT filings assessed for conviction, transaction quality, insider breadth, clustering, freshness, and price confirmation.
80/100
Conviction accumulation
47/100 confidence- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Latest evidence
- 12 Jun 2026
Investment committee read
Conviction accumulation
Priced common-share acquisitions carry more weighted evidence than disposals after freshness, role, size, and duplicate controls.
Research constructive setupsDecision risks
- The latest qualifying filing is more than 30 days old.
Price confirmation map
Weekly price with common-share events
Acquisitions and disposals are aligned to the nearest completed weekly bar.
Feb 2025Aug 2026
Weekly closeCommon-share acquisitionCommon-share disposal
Market confirmation
Price and trend context
- Latest close
- 13.96 USD
- One-week move
- +7.2%
- Four-week move
- -8.5%
- Fair-value gap
- -2.8%
- Trend signal
- Inactive
- Relative strength
- -32.4
Directional balance
Controlled event mix
100.0%acquisition
- Acquisition events
- 4
- Disposal events
- 0
- Net value
- $103.6M
Cadence
Twelve-week filing pressure
Volume shows attention. Controlled events determine direction.
025 May
401 Jun
208 Jun
015 Jun
022 Jun
029 Jun
006 Jul
013 Jul
020 Jul
027 Jul
003 Aug
010 Aug
Named participants
Insider conviction by person
DUGGAN, ROBERT WDirector, Co-Chief Executive Officer, 10% Owner752 events
SONI, MANMEET SINGHDirector, COO and CFO752 events
ZANGANEH, MAHKAMDirector, Co-Chief Executive Officer, 10% Owner752 events
Evidence quality
Security and transaction context
Role architecture
Who is participating
Transaction evidence
Auditable SMMT filing ledger
Showing 1 to 6 of 6.
DUGGAN, ROBERT WDirector, Co-Chief Executive Officer, 10% Owner
AcquisitionCommon equity
3810000 sharesCommon Stock
$50.0MDirectional evidence
ZANGANEH, MAHKAMDirector, Co-Chief Executive Officer, 10% Owner
AcquisitionCommon equity
3810000 sharesCommon Stock
$50.0MDirectional evidence
DUGGAN, ROBERT WDirector, Co-Chief Executive Officer, 10% Owner
AcquisitionCommon equity
100000 sharesCommon Stock
$1.5MDirectional evidence
ZANGANEH, MAHKAMDirector, Co-Chief Executive Officer, 10% Owner
AcquisitionCommon equity
100000 sharesCommon Stock
$1.5MDirectional evidence
SONI, MANMEET SINGHDirector, COO and CFO
AcquisitionCommon equity
25000 sharesCommon Stock
$361.5KDirectional evidence
SONI, MANMEET SINGHDirector, COO and CFO
AcquisitionCommon equity
25000 sharesCommon Stock
$360.8KDirectional evidence
Reading the dossier
Direction and confidence are separate
Conviction
The 0 to 100 score classifies deduplicated priced common-share evidence. Fifty is balanced or non-directional.
Confidence
Confidence rises with controlled event depth, named-insider breadth, fresh evidence, normalized values, and a longer observation span.
Disposals
Selling is not treated as the mirror image of buying. It carries less directional weight because taxes, diversification, compensation, and planned transactions can all create sales.
Price confirmation
The market chart tests whether the filing thesis is being confirmed or rejected by price, fair-value position, relative strength, and the current trend state.
Independent market research for education. This classification is not investment advice, a recommendation, a forecast, or an execution instruction.